Association of Benign Prostate Hyperplasia with Polymorphisms in VDR, CYP17, and SRD5A2 Genes among Lebanese Men

Abstract

Background: The aim of the study was to investigate any associations between benign prostate hyperplasia (BPH) and single nucleotide polymorphisms (SNPs) in the VDR gene (FokI, BsmI, ApaI and TaqαI loci) and the CYP17 gene (MspA1I locus), as well as TA repeat polymorphism in SRD5A2 gene among Lebanese men. Materials and Methods: DNA extracted from blood of 68 subjects with confirmed BPH and 79 age-matched controls was subjected to PCR/PCR-restriction fragment length polymorphism analysis. The odds ra=tio (OR) of having a genotype and the relative risk (RR) of developing BPH for having the genotype were calculated and the alleles were designated risk-bearing or protective. Results: Our data indicated that the A and B alleles of the VDR ApaI and BsmI SNPs were highly associated with increased risk of BPH (p=0.0168 and 0.0002, respectively). Moreover, 63% of the controls compared to 43% of the subjects with BPH were homozygous for none of the risk-bearing alleles (p=0.0123) whereas 60% of the controls and 28% of the subjects with BPH were homozygous for two or more protective alleles (p<0.0001). Conclusions: For the first time, our study demonstrated that ApaI and BsmI of the VDR gene are associated with risk of BPH among Lebanese men. Our study also indicated that overall polymorphism profile of all the genes involved in prostate physiology could be a better predictor of BPH risk.

Association of VDR polymorphisms (Taq I and Bsm I) with prostate cancer: a new meta-analysis

“…A total of six case–control studies about the Bsm I (rs1544410) polymorphism and the relationship between prostate cancer were identified. 30 , 32 – 35 , 37 These included a total of 1,555 prostate cancer patients (350 Asians, 816 Caucasians, and 389 African Americans) and 1,376 controls (369 Asians, 870 Caucasians, and 137 African Americans). In these studies, the Bsm I (rs1544410) allele frequency was in line with the HWE (χ 2 test, P > 0.05) ( Table 1 ).…”

Vitamin D Receptor Polymorphism and Cancer: An Update

“…However, the association varies with race (Asian, Caucasian, and African-American) and the genotypephenotype-based relationship of VDR. Recently, a case-control study investigating the possible associations of VDR polymorphism (FokI, BsmI, ApaI and TaqαI), and the cytochrome P-45017 alpha (CYP17) gene (the MspA1I locus) with prostate cancer among Lebanese men suggested that the overall polymorphism profile of every gene involved in prostate physiology is a better indicator than polymorphisms in individual genes (45). Table III).…”

Human Kallikrein-2, Prostate Specific Antigen and Free-Prostate Specific Antigen in Combination to Discriminate Prostate Cancer from Benign Diseases in Syrian Patients

“…In Middle East countries it may be less common; but is still one of the most common cancers in men with elevated incidence especially in Lebanon and Syria (Salim et al, 2009;Shamseddin et al, 2014). Take into consideration the possibility associations between Prostate Cancer with genetic, familial, environmental and other factors, also the effect of different measures or detection programs applied in the different countries and the awareness variation of people toward these programs (Boyle et al, 2003;Arafa et al, 2012;Ezzi et al, 2014;Baade et al, 2015;Choubey et al, 2015) The prostate cancer had few specific symptoms in its early stage, for that reason, detecting cancer holds several difficult. The standard practice of screening for prostate cancer includes PSA, with or without digital rectal exam test (DRE), starting at the age of 50 years in all males or earlier in men with certain risk factors.…”